Sonova stock steadies as hearing care leader focuses on earnings momentum

Sonova stock reflects the Swiss hearing care groups latest earnings trajectory, with investors weighing fiscal 2023-24 revenue growth and profitability alongside recent margin guidance and acquisition spending.

Sonova Holding AG (ISIN CH0012549785) reported higher revenue and earnings for its fiscal year 2023-24, giving Sonova stock a backdrop of expanding sales and profits as investors assess the Swiss hearing care leaders positioning in the global medtech sector. According to the companys annual results release dated 21 May 2024, Sonova generated CHF 3.86 billion in consolidated sales in fiscal 2023-24, an increase of 11.5 percent over the previous year on a reported basis and 9.1 percent in local currencies according to Sonovas 2023-24 annual report. The same report shows that adjusted EBITA rose to CHF 964.4 million, up 10.7 percent in local currencies from the prior year, underlining that profitability broadly kept pace with revenue expansion in the period ended 31 March 2024.

Revenue up 11.5 percent in 2023-24

In its detailed fiscal 2023-24 financial statements, Sonova highlighted that the Hearing Instruments segment, which includes hearing aids and audiological care, remained the largest contributor to group revenue. For the year ended 31 March 2024, Hearing Instruments sales reached CHF 3.30 billion, compared with CHF 2.93 billion a year earlier, implying segment growth of roughly CHF 370 million or about 12.5 percent year on year according to Sonovas FY 2023-24 results presentation. The group reported that Cochlear Implants revenue came in at CHF 561 million for the same period, up from CHF 537 million in the previous year, which corresponds to growth of about 4.5 percent in Swiss francs as the segment continued to recover from earlier supply disruptions.

On the earnings side, Sonova stated that basic earnings per share (EPS) for fiscal 2023-24 reached CHF 10.76, compared with CHF 9.98 in the prior year, representing an increase of around 7.8 percent based on Sonovas annual report for 2023-24. The adjusted EBITA margin for the group was reported at 25.0 percent in fiscal 2023-24, slightly lower than the 25.4 percent level recorded a year earlier, as the company balanced higher volumes and operating leverage with continued investments in research, development and marketing.

Guidance, cash flow and shareholder returns

Looking ahead, Sonova has guided for further growth in its current fiscal year. In its outlook section issued on 21 May 2024, the company forecast mid single-digit to high single-digit percentage growth in sales and adjusted EBITA in local currencies for fiscal 2024-25, as it continues to integrate acquired businesses and expand its audiological care footprint according to the outlook section of the 2023-24 report. For investors, the guidance underlines that the company is targeting another year of positive top-line and profit development, albeit from a higher base after the double-digit revenue expansion in 2023-24.

Cash generation remains a key part of Sonovas equity story. The company reported operating free cash flow of CHF 792 million in fiscal 2023-24, compared with CHF 707 million in the previous year, which represents an increase of about 12.0 percent based on the FY 2023-24 financial results. According to the same disclosure, Sonova proposes a dividend of CHF 5.20 per share for fiscal 2023-24, up from CHF 4.90 per share a year earlier, which corresponds to a year-on-year increase of 6.1 percent and reflects the boards confidence in the companys cash flow profile.

Phonak hearing aids anchor portfolio

Within Sonovas product portfolio, the Phonak brand remains one of the most recognizable names in hearing aids worldwide. Phonak offers a wide range of behind-the-ear and in-the-ear devices, including rechargeable and Bluetooth-enabled models aimed at improving speech understanding in challenging listening environments. According to Sonovas product information and segment reporting, hearing instruments, including Phonak devices and related services, accounted for the majority of the CHF 3.30 billion Hearing Instruments segment revenue in fiscal 2023-24, underscoring how central the brand is to the groups financial performance as shown in Sonovas brand overview for Phonak. For investors, the continued innovation cadence in areas such as connectivity, battery life and audiological performance is a key factor in maintaining Sonovas competitive position in both developed and emerging markets.

Sonova stock and market context

Sonova shares trade on SIX Swiss Exchange, where the company is a component of the SMI index that tracks large Swiss blue chips. According to a recent Sonova share data overview from a Swiss market portal, the companys market capitalization stood at approximately CHF 18.5 billion as of mid May 2024, shortly after the release of the 2023-24 annual report, reflecting the markets assessment of Sonovas earnings power and growth prospects at that time based on SIX Swiss Exchange data for Sonova. The same data indicated a 52 week trading range that placed the share price meaningfully above its pandemic period lows, although the stock has seen periods of volatility linked to broader moves in healthcare and interest rate sensitive equities.

For market participants, the key variables now include Sonovas ability to convert its guidance for fiscal 2024-25 into continued growth in EPS and free cash flow, while managing cost inflation and competitive dynamics in hearing care and cochlear implants. With revenue in fiscal 2023-24 up 11.5 percent year on year and operating free cash flow up 12.0 percent, the company has demonstrated that its strategy of expanding its retail audiological care footprint and investing in technology can support both top-line and bottom-line progress. The coming reporting periods will show how resilient that trend remains as macroeconomic conditions and health-care reimbursement regimes evolve.

Sonova stock key facts

• Company: Sonova Holding AG
• ISIN: CH0012549785
• Ticker: SIX: SOON
• Trading venue: SIX Swiss Exchange
• Market capitalization: approximately CHF 18.5 billion (as of 21 May 2024)
• Sector / Industry: Health Care / Medical Devices
• Index membership: SMI